These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 2441838

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT, Kao CJ, Wolf M, DeGregorio MW.
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [Abstract] [Full Text] [Related]

  • 6. Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.
    Nishimura Y, Tomita Y, Yuno A, Yoshitake Y, Shinohara M.
    Cancer Sci; 2015 May; 106(5):505-11. PubMed ID: 25726868
    [Abstract] [Full Text] [Related]

  • 7. Adjuvant specific immunotherapy of resectable squamous cell lung carcinoma. Analysis at the eighth year.
    Takita H, Hollinshead A, Hart T, Bhayana J, Adler R, Rao U, Moskowitz R, Ramundo M.
    Cancer Immunol Immunother; 1985 May; 20(3):231-5. PubMed ID: 3904977
    [Abstract] [Full Text] [Related]

  • 8. The effect of specific and nonspecific immunotherapy on natural killer cell activity in patients with non-small-cell lung cancer.
    Maroun JA, Pross HF, Stewart TH, White MJ, Hyslop DB.
    J Clin Oncol; 1984 Nov; 2(11):1209-14. PubMed ID: 6491701
    [Abstract] [Full Text] [Related]

  • 9. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
    Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, Lopez-Brea M, Vanakesa T, Jassem J, Kalofonos H, Perdeus J, Bonnet R, Basko J, Janilionis R, Passlick B, Treasure T, Gillet M, Lehmann FF, Brichard VG.
    J Clin Oncol; 2013 Jul 01; 31(19):2396-403. PubMed ID: 23715567
    [Abstract] [Full Text] [Related]

  • 10. Antitumor vaccination: where we stand.
    Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, Lanata L, Lemoli RM, Massaia M, Rondelli D, Zanon P, Tura S.
    Haematologica; 2000 Nov 01; 85(11):1172-206. PubMed ID: 11074658
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma.
    Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, Mirlacher M, Gambazzi F, Harder F, Heberer M, Sauter G, Spagnoli GC.
    Ann Surg; 2002 Dec 01; 236(6):785-93; discussion 793. PubMed ID: 12454517
    [Abstract] [Full Text] [Related]

  • 13. Antigenic epitopes of three tumor-associated antigens of well-differentiated squamous cell carcinoma of the larynx for use in monitoring patients in specific active immunochemotherapy trials.
    Hollinshead AC.
    Cancer Detect Prev; 1987 Dec 01; 10(3-4):153-8. PubMed ID: 2436778
    [Abstract] [Full Text] [Related]

  • 14. Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease.
    Brichard VG, Lejeune D.
    Expert Opin Biol Ther; 2008 Jul 01; 8(7):951-68. PubMed ID: 18549325
    [Abstract] [Full Text] [Related]

  • 15. Active-specific immunotherapy for melanoma.
    Mitchell MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WD, Dean G, Stevenson L.
    J Clin Oncol; 1990 May 01; 8(5):856-69. PubMed ID: 2139701
    [Abstract] [Full Text] [Related]

  • 16. Active specific immunotherapy of stage IV renal carcinoma with aggregated tumor antigen adjuvant.
    Neidhart JA, Murphy SG, Hennick LA, Wise HA.
    Cancer; 1980 Sep 01; 46(5):1128-34. PubMed ID: 7214296
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.
    Harris JE, Ryan L, Hoover HC, Stuart RK, Oken MM, Benson AB, Mansour E, Haller DG, Manola J, Hanna MG.
    J Clin Oncol; 2000 Jan 01; 18(1):148-57. PubMed ID: 10623705
    [Abstract] [Full Text] [Related]

  • 18. Specific active immunotherapy in lung cancer: the induction of long-lasting cellular responses to tumour-associated antigens.
    Stewart T, Hollinshead AC, Harris JE, Raman S.
    Recent Results Cancer Res; 1982 Jan 01; 80():232-9. PubMed ID: 7036287
    [No Abstract] [Full Text] [Related]

  • 19. Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy.
    Babiak A, Steinhauser M, Götz M, Herbst C, Döhner H, Greiner J.
    Oncol Rep; 2014 Jan 01; 31(1):384-90. PubMed ID: 24154794
    [Abstract] [Full Text] [Related]

  • 20. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
    Eton O, Kharkevitch DD, Gianan MA, Ross MI, Itoh K, Pride MW, Donawho C, Buzaid AC, Mansfield PF, Lee JE, Legha SS, Plager C, Papadopoulos NE, Bedikian AY, Benjamin RS, Balch CM.
    Clin Cancer Res; 1998 Mar 01; 4(3):619-27. PubMed ID: 9533529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.